|
July 30, 2010
|
| 16:01 EDT |  | GENZ |
| theflyonthewall.com: | Options Update; July 30 2010 | | Volatility Index-VIX down 47c to 23.66. CBOE option volume leaders today: GENZ ARNA BAC AAPL. :theflyonthewall.com |
|
| 07:39 EDT |  | GENZ |
|
|
July 29, 2010
|
| 16:00 EDT | | GENZ |
|
| 12:04 EDT |  | GENZ |
| theflyonthewall.com: | On The Fly: European Markets Wrap-Up | | Stocks in Europe were mostly lower as a number of markets declined...Last month European confidence in the economy--despite Greece's budget crisis--climbed to the highest level in over two years...UNITED KINGDOM: The FTSE 100 Index fell 5.73 to 5,313.95...GERMANY: The DAX Index lost 44.24 to 6,134.70...Deutsche Lufthansa (DLAKY) profit rose as freight transportation jumped and travel increased...FRANCE: The CAC 40 Index slipped 18.45 to 3,651.91...Sanofi-aventis (SNY) reportedly will offer up to $70 a share for Genzyme (GENZ)...AROUND EUROPE: Online gambling firm PartyGaming Plc is expected to buy Bwin Interactive Entertainment AG in a reverse takeover worth $1.76B. :theflyonthewall.com |
|
| 10:20 EDT | | GENZ |
| theflyonthewall.com: | Genzyme downgraded to Hold from Buy at Lazard Capital | | :theflyonthewall.com |
|
| 09:49 EDT | | GENZ |
|
| 09:16 EDT |  | GENZ |
|
| 09:16 EDT |  | GENZ |
| theflyonthewall.com: | Sanofi expected to send bear hug letter to Genzyme in next 72 hours, CNBC says | | :theflyonthewall.com |
|
| 08:40 EDT |  | GENZ |
| theflyonthewall.com: | Genzyme likely needs $85 per share to be interested in selling, says Jefferies |
 Subscribe for More Information :theflyonthewall.com |
|
| 07:42 EDT |  | GENZ |
| theflyonthewall.com: | Rising drugs costs hit Europe, WSJ reports | | Europe has joined the U.S. in feeling the squeeze of rising drug costs, and a number of countries are responding by reducing the prices they'll pay, hurting drug company profits, reports the Wall Street Journal. Reference Link :theflyonthewall.com |
|
| 07:29 EDT | | GENZ |
|
| 06:50 EDT | | GENZ |
| theflyonthewall.com: | Sanofi-Aventis likely to bid up to $70 per share for Genzyme, NY Times says | | Sanofi-Aventis (SNY) will likely make an unsolicited bid of up to $70 per share, or about $18.6B, for Genzyme (GENZ), according to the New York Times, citing unnamed people familiar with the matter. Sanofi's board reportedly approved the bid yesterday. Sanofi will likely issue a letter that will signal the company's willingness to make its bid hostile if necessary, the sources add. Reference Link :theflyonthewall.com |
|
|
July 28, 2010
|
| 16:46 EDT | | GENZ |
|
| 13:52 EDT | | GENZ |
| theflyonthewall.com: | Genzyme downgraded to Hold from Buy at Argus | | :theflyonthewall.com |
|
|
July 27, 2010
|
| 13:46 EDT | | GENZ |
| theflyonthewall.com: | Genzyme says encouraged by CMS decision | | Genzyme said it welcomed the Centers for Medicare and Medicaid Services', or CMS, decision not to include oral medications without IV equivalents in Medicare’s End Stage Renal Disease patient benefit. According to the final rule, these medications, including Genzyme’s Renvela, will not be included in the bundle until January 1, 2014. "Genzyme is encouraged by CMS’ final decision, as we believe it will put the needs of the patients first by providing the time needed to collect data to document the current standard of care, enabling assessment in the future of any unintended negative consequences that the new bundled payment system may have on the management and outcomes of dialysis patients," the company said. :theflyonthewall.com |
|
| 12:04 EDT | | GENZ |
| theflyonthewall.com: | Call strike with large percentage moves: GENZ AIG S | | Genzyme (GENZ) August 70 call volatility decreased 13%. AIG (AIG) August 48 call volatility increased 6%. Sprint (S) August 4 call volatility increased 18% according to IVolatility's RT Options Scanner. :theflyonthewall.com |
|
| 07:44 EDT | | GENZ |
|
|
July 26, 2010
|
| 13:08 EDT | | GENZ |
| theflyonthewall.com: | Call strike with large percentage moves: GENZ WY RSH | | Genzyme (GENZ) August 70 call volatility decreased 13%. Weyerhaeuser (WY) August 19 call volatility increased 3%. Radio Shack (RSH) August 24 call volatility increased 5% according to IVolatility's RT Options Scanner. :theflyonthewall.com |
|
| 11:58 EDT | | GENZ |
| theflyonthewall.com: | BNP, JP Morgan said to agree to finance Sanofi's Genzyme offer, Bloomberg says | | :theflyonthewall.com |
|
| 11:55 EDT | | GENZ |
|
| 11:50 EDT | | GENZ |
|
| 09:21 EDT | | GENZ |
|
| 09:02 EDT | | GENZ |
|
| 08:39 EDT | | GENZ |
|
| 08:26 EDT | | GENZ |
|
| 08:21 EDT | | GENZ |
| theflyonthewall.com: | Genzyme levels to watch | | The shares are trading up over 5% in the pre-market, following a report in the WSJ that GlaxoSmithKline (GSK) had made "very casual approach" to the company. With the stock potentially in play, traders are bidding up the shares further from Friday's big gains. At the current pre-market price of $66, the shares have cleared resistance at the 200-week moving average, last at $63.33. Resistance levels to watch as potential upside objectives are at $66.80, $67.57, $68.92. :theflyonthewall.com |
|
| 07:01 EDT | | GENZ |
|
| 06:42 EDT | | GENZ |
|
| 06:20 EDT | | GENZ |
|
|
July 23, 2010
|
| 16:11 EDT | | GENZ |
| theflyonthewall.com: | Genzyme August volatility at 54, October at 42, January at 34 | | Genzyme closed up $8.35 to $62.52. The WSJ reported Sanofi-Aventis (SNY) made an informal acquisition approach to GENZ. GENZ call option volume of 29K contracts compares to put volume of 8K contracts. August put option implied volatility is at 54, October is at 42, January is at 34; verses its six-month average of 31 according to Track Data, suggesting larger price movement. :theflyonthewall.com |
|
| 13:50 EDT | | GENZ |
|
| 13:46 EDT | | GENZ |
|
| 13:45 EDT | | GENZ |
| theflyonthewall.com: | Allergan volatility up; shares down on report of Sanofi interest in Genzyme | | Allergan (AGN) is recently down $1.73 to $60.80. The WSJ reported Sanofi-Aventis (SNY) made an informal acquisition approach to Genzyme (GENZ). AGN August put option implied volatility is at 44, October is at 37, October is at 37; above its 26-week average of 30 according to Track Data, suggesting larger price movement. :theflyonthewall.com |
|
| 13:31 EDT | | GENZ |
|
| 13:30 EDT | | GENZ |
| theflyonthewall.com: | Genzyme surges following reports of unsolicited takeover offer | | Genzyme (GENZ) shares surged after the Wall Street Journal, followed by CNBC, reported that Sanofi-Aventis (SNY) made an informal acquisition offer for the company. The approach was a month ago, and Sanofi-Aventis is now considering a hostile offer given Genzyme's desire to remain independent, according to CNBC's David Faber. TheFly notes that Biogen (BIIB) and Allergan (AGN) traded lower on the news, as both stocks rallied when it was reported Sanofi-Aventis was looking to make an acquisition in the U.S. :theflyonthewall.com |
|
| 13:24 EDT | | GENZ |
| theflyonthewall.com: | Genzyme trading resumed | | :theflyonthewall.com |
|
| 13:22 EDT | | GENZ |
|
| 13:22 EDT | | GENZ |
|
| 13:21 EDT | | GENZ |
| theflyonthewall.com: | Sanofi-Aventis approached Genzyme in last month, CNBC reports | | :theflyonthewall.com |
|
| 13:21 EDT | | GENZ |
|
| 13:20 EDT | | GENZ |
| theflyonthewall.com: | Biogen moves lower following news Sanofi-Aventis has approached Genzyme | | :theflyonthewall.com |
|
| 13:20 EDT | | GENZ |
|
|
July 22, 2010
|
| 09:14 EDT | | GENZ |
|
|
July 21, 2010
|
| 08:24 EDT | | GENZ |
| theflyonthewall.com: | Genzyme says in the process of evaluating its global organization | | Genzyme has retained independent consultants and has begun identifying potential efficiencies and cost reductions to improve its operating margins. The company is in the process of evaluating its global organization and cost structure to develop a multi-year action plan which will be implemented beginning this fall. The company has made progress in its efforts to find strategic alternatives for its Genetics, Diagnostics, and Pharmaceuticals businesses, and is on-track to complete transactions by the end of this year. :theflyonthewall.com |
|
| 08:23 EDT |  | GENZ |
|
| 08:23 EDT | | GENZ |
|
| 08:23 EDT | | GENZ |
|
| 08:22 EDT | | GENZ |
| theflyonthewall.com: | Genzyme reports Q2 EPS 18c vs. consensus of 51c | | Reports Q2 revenue $1.08B vs. consensus of $1.16B. Non-GAAP figures include pre-tax manufacturing write-offs of $21.9M primarily for material that had to be discarded following the interruption in operations at the Allston facility late in the first quarter and for costs associated with the temporary shutdown of the company’s Haverhill, U.K., facility in December 2009. These figures also include a pre-tax write-down of $32.3M for the company’s 2008 equity investment in Isis Pharmaceuticals, reflecting the extent to which the share price paid exceeds the current market value. Non-GAAP net income excludes stock compensation expenses and costs associated with the acquisition of oncology products from Bayer. :theflyonthewall.com |
|
| 08:21 EDT | | GENZ |
| theflyonthewall.com: | Genzyme: Expects to be able to increase shipments of Cerezyme, Fabrazyme in 2H | | :theflyonthewall.com |
|
